Aluminum-Binding Fusion Polypeptides for Local Tumor Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immunomodulatory polypeptides, such as cytokines, face dose-limiting toxicities and challenges in maintaining therapeutic efficacy due to systemic exposure, necessitating improved delivery methods.
Innovation Solution
Development of fusion polypeptides conjugated with metal hydroxides, particularly aluminum hydroxide, which form complexes that persist at the injection site, enhancing tumor microenvironment efficacy and reducing systemic toxicity through improved retention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunomodulatory polypeptides are administered systemically to achieve therapeutic efficacy, then tumor treatment effectiveness is improved, but systemic toxicity increases and becomes dose-limiting
Solution Approach 1:
The patent applies local quality by engineering polypeptides with specific aluminum-binding domains that enable selective accumulation at the injection site (tumor microenvironment) while limiting systemic distribution. The aluminum-complexing capability is localized to the polypeptide structure, creating a region-specific therapeutic effect that spares other organs from toxic exposure
Solution Approach 2:
Aluminum hydroxide particles serve as an intermediary carrier that mediates between the polypeptide drug and the tumor microenvironment. The aluminum particles bind the polypeptides and provide a sustained release mechanism, acting as a depot that localizes the therapeutic agent at the injection site and controls its release kinetics to minimize systemic exposure
2Object-affected harmful factors
If immunomodulatory polypeptides are administered by intratumoral injection to reduce systemic toxicity, then localized retention is improved, but therapeutic efficacy may be compromised due to limited distribution
Solution Approach 1:
The engineered polypeptides possess multiple functions: they maintain the immunomodulatory activity of the parent polypeptide, acquire aluminum-binding capability for localized retention, and provide sustained release from aluminum particles. This multi-functionality allows a single intratumoral injection to achieve both localized retention and sufficient therapeutic effect without requiring systemic distribution
3Duration of action of stationary object
If fusion polypeptides with aluminum-binding capability are developed to enhance localized retention, then persistence at injection site is improved, but molecular complexity increases
Solution Approach 1:
The polypeptide is segmented into functional domains: an N-terminal or C-terminal aluminum-binding domain containing specific amino acid sequences (e.g., polybasic regions, phosphorylation sites) and a linker region connecting to the immunomodulatory polypeptide. This segmentation allows independent optimization of each function while maintaining overall simplicity through modular design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion polypeptides demonstrate enhanced tumor treatment efficacy as monotherapy or in combination with other therapies, with improved retention and reduced systemic toxicity.
Implementation Method 1
polypeptides amenable to phosphorylation can adsorb to alum much more strongly when in their phosphorylated form
Implementation Method 2
polypeptides amenable to phosphorylation can adsorb to alum much more strongly when in their phosphorylated form (i.e., where phosphate groups have replaced hydroxyl groups)
Data Source
AI summary
The present disclosure provides surprisingly useful fusion polypeptides including an immunomodulatory moiety and a metal-hydroxide binding moiety, as well as various related technologies, including methods of making and of using such fusion polypeptides.